Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05179824 · ClinicalTrials.gov registry record
Tempus Priority Study: A Pan-tumor Observational Study
A clinical trial of Breast Cancer and Prostate Cancer, sponsored by Tempus AI.
- Active
- Registry status
- 1,000
- Enrollment target
- 2
- Study locations
NCT05179824: Active study of Breast Cancer and Prostate Cancer, sponsored by Tempus AI.
NCT05179824 is a study of Breast Cancer and Prostate Cancer that is active but no longer recruiting, run by Tempus AI. The registered enrollment target is 1,000 participants, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (64% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05179824, a study of Breast Cancer and Prostate Cancer, is active but no longer recruiting, sponsored by Tempus AI.
- ACTIVE NOT RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 2
- Study locations
Study Summary
Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with the goal of conducting research to advance cancer care and create a dataset that furthers cancer research.
Primary Outcome
To create a robust data set of health information about cancer patients who receive comprehensive genomic profiling in order to facilitate future novel precision medicine research
Conditions Studied
Interventions
- OTHER Observation
Study Locations (2)
Texas
- UT Southwestern - Dallas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2020-10-19 |
| Est. Completion | 2030-10-19 |
What the registry record for NCT05179824 still lists
NCT05179824 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (64% lower).
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Observation is the first listed.
NCT05179824 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05179824 about?
NCT05179824 is a clinical study titled "Tempus Priority Study: A Pan-tumor Observational Study". Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with the goal of conducting research to advance cancer care and create a da...
What is the current status of trial NCT05179824?
This trial is currently active not recruiting. The enrollment target is 1,000 participants. The study started on 2020-10-19. Estimated completion is 2030-10-19.
What conditions does trial NCT05179824 study?
This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer.
What interventions are being tested in trial NCT05179824?
The interventions under investigation include: Observation (OTHER).
Who is sponsoring clinical trial NCT05179824?
This trial is sponsored by Tempus AI, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05179824 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05179824's enrollment target sits among peer trials
1,000 120th of 1224 higher than 1,097 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI